

PROVIDER Update



CONTRACTUAL | JANUARY 4, 2024 | UPDATE 24-018m | 3 PAGES

Medication Trend Updates and Formulary Changes – 1st Quarter 2024

Review formulary changes and medication safety issues

Stay up to date with information about:

- FDA updated boxed warnings to improve safe use of prescription stimulants to treat attention-deficit/hyperactivity disorder (ADHD).
- Changes to the Health Net*, on behalf of CalViva Health, commercial Formulary, Medi-Cal Preferred Drug List (PDL) and Medicare Part D Formulary for the first quarter of 2024.

FDA updated boxed warnings to improve safe use of prescription stimulants to treat ADHD

In an effort to address the harms of misuse and abuse of stimulants prescribed to treat conditions such as ADHD, the U.S. Food and Drug Administration updated warnings on the labels of prescription stimulants.

The updated boxed warnings in the prescribing information for the entire class of prescription stimulants will include information about the risks of abuse, misuse, addiction, and overdose, as well as language advising physicians to monitor patients closely for these risks. Commonly prescribed drugs in this class include amphetamine/dextroamphetamine (Adderall), methylphenidate (Concerta), dextroamphetamine (Dexedrine), lisdexamfetamine dimesylate (Vyvanse), and methylphenidate (Ritalin). These medications are indicated for the management of ADHD as well as eating disorders and narcolepsy.

This labeling update was based on a review of medical literature (between January 2006 and May 2020) on nonmedical use of prescription stimulants. Family members and friends were the most common source of prescription stimulants for nonmedical use. According to the literature, use of prescription stimulants by individuals who were not prescribed these medications has been associated with a higher risk of developing substance use disorder and addiction.

The new labeling advises health care professionals to monitor patients for obvious signs of abuse or addiction. Patients should be counseled not to share their prescribed stimulants with anyone else. Health care providers are encouraged to educate both patients and families about the serious risks of these drugs as well as proper storage and disposal of any unused medicine. In addition, careful records

THIS UPDATE APPLIES TO MEDI-CAL PROVIDERS:

- Physicians
- Participating Physician Groups

PROVIDER SERVICES

CalViva Health Medi-Cal (including ECM and CS providers) –
888-893-1569

Behavioral health providers –
844-966-0298

PROVIDER PORTAL

provider.healthnetcalifornia.com

should be kept that indicate the quantity, frequency, and renewal requests for these medications.

Drug benefit changes

The Pharmacy and Therapeutics (P&T) Committee includes practicing physicians, pharmacists and other health care professionals. Each quarter, the P&T Committee reviews medications on the Formulary for commercial members, the PDL for Medi-Cal members, and the Medicare Part D Formulary for Medicare members to determine which medications remain on the same tier and which are moved. A table listing some recent changes is available on page 3. The list contains brand-name prescription medications, status, other medication choices, and comments for the first quarter of 2024.

The complete lists of the commercial Formularies, Medi-Cal PDLs and Medicare Part D Formularies are available on the Plan provider website.

Pharmacy help line

For more information regarding changes to the Medi-Cal medical benefit drugs, contact the proper pharmacy phone number listed.

Product	Phone number	Fax number
Pharmacy Benefit (Medi-Cal Rx)	800-977-2273	800-869-4325
Medical Benefit Drugs (Medi-Cal)	800-675-6110	833-953-3436

Additional information

Providers are encouraged to access the provider portal online at provider.healthnetcalifornia.com for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update, contact CalViva Health at 888-893-1569.

Changes to the CalViva Health Medi-Cal Preferred Drug benefits

Medication	Status	Formulary alternative(s)	Comments
Oral preparation			
Zurzuvae™ (zuranolone) capsule	Carved out to State		Treatment of postpartum depression in adults
Injectable preparation			
Adalimumab-adaz injection by Sandoz	Carved out to State		Now preferred for commercial line of business; biosimilar to Humira.
Amjevita™ (adalimumab-atto) injection	Carved out to State		Nonpreferred for commercial line of business; biosimilar to Humira.
Elevidys™ (delandistrogene moxparvovec-rokl) suspension for intravenous infusion	Medical Benefit ¹		Treatment of ambulatory pediatric patients aged four through five years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.
Hadlima (adalimumab-bwvd) injection	Carved out to State		Now preferred for commercial line of business; biosimilar to Humira.
Roctavian™ (valoctocogene - roxaparvovec-rvox) suspension for intravenous infusion	Medical Benefit ¹		Treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity < 1 IU/dL) without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test.
Topical preparation			
Vyjuvek™ (beremagene geperpavec-svdt) suspension for topical application	Carved out to State		Treatment of wounds in patients six months of age and older with dystrophic epidermolysis bullosa (DEB) with mutations(s) in the collagen type VII alpha 1 chain (COL7A1) gene.

Note: The information above is subject to change. Please refer to Health Net website for the most up-to-date formulary status.

¹Prior authorization (PA) is required to verify that the member is eligible and satisfies clinical protocols to ensure appropriate use of the medication.